A PSEN1 genetic test looks for mutations in the presenilin-1 gene, the single most common cause of early-onset familial Alzheimer's disease, found in up to roughly 70% of cases where strong family history points to an inherited cause (versus about 15% for the APP gene and under 5% for PSEN2), which is why it's typically the first gene checked in a panel for a younger adult with memory problems, according to ARUP Consult's Early-Onset Alzheimer's Panel guidance. The test itself is usually ordered as part of a combined panel covering APP, PSEN1, and PSEN2, run from a blood sample with results back in 10 to 15 days. For someone already showing symptoms before age 65, with a family history of early dementia, that panel detects a causative variant in roughly 60-80% of true early-onset familial cases, per ARUP Laboratories' test documentation. Cost and insurance coverage depend heavily on whether the person being tested has symptoms or is an unaffected relative seeking to know their own risk, and both paths require genetic counseling before and after the blood draw.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Table of Contents
- Who actually qualifies for this test?
- What does the test cost out of pocket?
- Will insurance cover it, and what has to happen first?
- What happens during pretest and posttest counseling?
- What to bring to the referral conversation
- Frequently Asked Questions
Who actually qualifies for this test?
Genetics practice guidance points to two distinct groups, and the referral path differs for each. The first group is symptomatic patients: people under 65 who are already experiencing memory loss or cognitive decline, especially when a parent, sibling, or other close relative also developed dementia young. A guideline summary from Guideline Central states this group should be offered testing even when family history is unclear, not only when it's well documented, according to its summary of genetic counseling and testing for Alzheimer disease. The second group is asymptomatic adults, 18 or older, who have a known family mutation.
This is predictive or presymptomatic testing, meaning the person feels fine but wants to know whether they carry the same PSEN1 variant that affected a parent or sibling. That same guideline recommends a baseline neurologic exam for these relatives before testing, rather than jumping straight from a family diagnosis to a blood draw. The distinction matters for insurance, too. Commercial payers evaluate symptomatic testing and predictive testing as separate scenarios with separate requirements, which is covered in Section 3 below. A primary care doctor or neurologist handling a younger patient with memory concerns, or a family member asking about their own risk, should know which category applies before making the referral.
What does the test cost out of pocket?
List prices for multi-gene early-onset Alzheimer's panels that include PSEN1 run from roughly $990 to $2,500 at commercial labs, based on comparable panel pricing cited in a 2025 University of Wisconsin presentation on genetic counseling and testing in dementia. That figure is the list price before any insurance processing, and it's the number a self-pay patient should expect if coverage falls through entirely. The same presentation gives a more realistic range for insured patients: a typical out-of-pocket cost between $0 and $1,000, usually landing around $300 once insurance has processed the claim.
The gap between the list price and that $300 figure is coverage doing its job — which is why confirming coverage before the blood draw, rather than after, is worth the extra step. Coverage isn't guaranteed everywhere. In Australia, for example, PSEN1 testing carries no Medicare rebate at all, so patients there pay the full cost unless a state genetics service absorbs it, according to Pathology Tests Explained, published by the Royal College of Pathologists of Australasia. That's a useful reminder that coverage rules are set jurisdiction by jurisdiction and insurer by insurer — being clinically appropriate for testing doesn't automatically mean a payer will pay for it.
Will insurance cover it, and what has to happen first?
U.S. commercial insurers generally split coverage the same way the clinical guidelines do: symptomatic testing and predictive testing are evaluated under different conditions. Highmark's commercial medical policy for Pennsylvania covers PSEN1, PSEN2, and APP testing as potentially medically necessary for symptomatic patients whose dementia began at age 65 or younger. It separately covers predictive testing for asymptomatic adults 18 or older, but only when a first- or second-degree relative already has a confirmed mutation, and only after pre- and post-test genetic counseling, according to Highmark's medical policy L-175-004.
Other insurers add similar conditions. Paramount's policy requires documented genetic counseling, confirmation that no prior test already would have caught the family's specific mutation, a qualifying family history, and — for asymptomatic testing specifically — a statement that the results will inform reproductive decisions, per Paramount Medical Policy PG0441. Blue Shield of California covers targeted testing when a close relative already carries a known PSEN1, PSEN2, or APP variant, and separately covers testing when a family history fits an autosomal-dominant pattern even if no relative has been tested yet, according to its medical policy on genetic testing for Alzheimer disease. A few things to check with the insurer or the testing lab before scheduling anything:.
- Has anyone in the family already been tested for the mutation? If so, that result, not a new test, may be what's needed.
- Has the referring provider documented pre-test genetic counseling? Most policies require this as a condition of payment, not just as good practice.
- Does the patient's age at symptom onset fall at or under 65? That threshold appears across multiple payer policies.
- For an asymptomatic relative, is there a confirmed mutation already identified in a first- or second-degree relative?
What happens during pretest and posttest counseling?
Testing labs don't just draw blood and run the panel. ARUP Laboratories' consent and ordering materials require informed consent for any presymptomatic adult being tested predictively, and recommend that a genetic counselor or the ordering provider walk the person through pretest and posttest counseling, according to ARUP's consent and ordering form. The same materials recommend bringing a support person to those conversations — specifically someone who is not themselves at risk for the mutation, since a sibling or child who could also carry it may not be in a position to offer steady support that day.
This isn't a formality insurers invented to slow things down; it reflects what a positive result actually means. A confirmed PSEN1 mutation in an asymptomatic adult is a predictive result for a condition with no cure, which is why guidelines recommend a baseline neurologic exam first and why counseling covers what a result would and wouldn't change about the person's life, insurance, and family planning before the sample is drawn. For someone reluctant to test now but who wants options preserved, DNA banking is a documented fallback: a sample is collected and stored without being analyzed, so testing can happen later without needing a new collection, per the Guideline Central summary referenced above.
What to bring to the referral conversation
A referring doctor or neurologist will move faster with specific information in hand rather than a general request for "genetic testing." Useful details to bring to that appointment: Because the standard panel sequences APP, PSEN1, and PSEN2 together rather than PSEN1 alone, a referral for "early-onset Alzheimer's genetic testing" will typically return results on all three genes in the same 10-to-15-day turnaround, not just the one most commonly implicated.
- The exact age the patient (or affected relative) first showed memory or cognitive symptoms.
- Which relatives were affected, how they were related, and whether any of them were ever tested.
- Whether a relative's mutation, if known, has already been identified as PSEN1 specifically, since that can shift which gene gets sequenced first.
- Current insurance plan name, since coverage conditions differ by policy as shown above.
Frequently Asked Questions
Is PSEN1 tested on its own, or as part of a panel?
It's typically run as part of a combined panel with APP and PSEN2, with results back in 10 to 15 days, according to ARUP Laboratories' test documentation.
Does a positive family history guarantee insurance coverage?
No. Insurers like Highmark and Paramount require documented pre- and post-test genetic counseling and, for predictive testing, a confirmed mutation already found in a close relative — a family history alone isn't sufficient under those policies.
What if someone doesn't want to test now but wants to preserve the option?
DNA banking stores a sample without analyzing it, allowing testing later without a new collection, per the Guideline Central summary.
Why does a support person matter for predictive testing?
ARUP's consent materials recommend the support person not be at risk for the same mutation, since a sibling or child who could also carry it may struggle to provide steady support on the day of counseling.
